Clinical trials: Cancer and / or Hematological Malignancy, open to volunteers
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients…
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Trial name
- NCT07424833
- Testing
- APG-3288
- Where
- 6 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Ascentage Pharma Group Inc.
Hematological Malignancy
KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
- Trial name
- NCT07873827
- Testing
- MEN2312
- Volunteers
- 115 people
- Sponsor
- Stemline Therapeutics, Inc.
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Solid Tumor, Hematological Malignancy
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease.
- Trial name
- BIP (NCT02534649)
- Testing
- Newly obtained biopsy and Blood samples collection
- Where
- 7 sites in France
- Volunteers
- 10,000 people
- Sponsor
- Institut Bergonié
Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity
BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across…
- Trial name
- BHF-COLLATE (NCT07864467)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Hematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
- Trial name
- MonumenTAL-1 (NCT04634552)
- Testing
- Talquetamab
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 510 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors, Hematological Malignancies
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a…
- Trial name
- NCT06224855
- Testing
- DXC006
- Where
- 5 sites in China
- Volunteers
- 280 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Solid and Hematological Malignancies, Autoimmune Diseases
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene…
- Trial name
- NCT05041309
- Testing
- Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 1,500 people
- Sponsor
- Kite, A Gilead Company
Hematological Malignancy (Leukemia- Lymphoma)
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in…
- Trial name
- NCT06948981
- Testing
- GT719 Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Grit Biotechnology
Hematological Malignancies
M-2018-334 in Hematological Malignancies
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
- Trial name
- HAPLO2022 (NCT06225050)
- Testing
- CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Miltenyi Biomedicine GmbH
Hematological Malignancies
A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of subjects with CD70-positive…
- Trial name
- NCT07809126
- Testing
- CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Hematological Malignancies
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and…
- Trial name
- NCT07809139
- Testing
- CHT101
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Cancer, Lung Cancer
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Optimal patient-centered care is often not being delivered to cancer patients, especially to vulnerable populations like those living in underserved rural areas.
- Conditions
- Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
- Trial name
- PRISMA (NCT07788729)
- Testing
- PRISMA-interventions
- Where
- 8 sites in Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- University of Regensburg
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
- Trial name
- NCT07220616
- Testing
- DS3790a, Combination drug
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 420 people
- Sponsor
- Daiichi Sankyo
Hematological Malignancy
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia.
- Trial name
- NCT05110742
- Testing
- Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
- Trial name
- NCT07137481
- Testing
- C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies, Invasive Fungal Disease
mNGS for IFD in Patients With Hematological Malignancies
Invasive fungal disease (IFD) refers to an infectious disease caused by fungi invading the human body, growing and reproducing in tissues, organs, or blood, and leading to inflammatory responses and tissue damage.
- Trial name
- NCT07763184
- Testing
- metagenomic next-generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Oral Mucositis, Total Body Irradiation
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing…
- Conditions
- Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- ChROMME-TBI (NCT07709195)
- Testing
- Sodium Copper Chlorophyllin
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Tata Memorial Centre